THERAPY DOSSIER · th-30c654f56269

VSL#3 probiotic mixture of live lyophilised Lactobacillus, Bifidobacterium and Streptococcus thermophilus, tested alone, heat-killed, and combined with glutamine

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01139736 ↗PHASE4completed

Manipulation of visceral hypersensitivity with probiotic bacteria in irritable bowel syndrome

Irritable Bowel Syndrome

Enrolment: 12 · Results not recorded

NCT02011542 ↗PHASE2/PHASE3terminated

Probiotics (VSL#3) for Gulf War Illness

Gulf War Illness

Enrolment: 29 · Results not recorded

NCT05608928 ↗PHASE2unknown

Ability of the probiotic Vivomixx to improve environmental enteropathy in pregnant women

Environmental Enteropathy

Enrolment: 76 · Results not recorded

NCT00852124 ↗PHASE1/PHASE2terminated

Safety of VSL#3 for adult asthmatics

Asthma

Enrolment: 3 · Results not recorded

NCT01032941 ↗PHASE1/PHASE2completed

Randomised controlled trial on beneficial effects of probiotics on portal haemodynamics in decompensated cirrhotic patients

Portal Hypertension

Enrolment: 18 · Results not recorded

NCT01877967 ↗NAunknown

Effect of dietary supplement VSL#3 on memory, attention, executive function and mood in healthy older adults

Alteration of Cognitive Function · Disturbance in Affect

Enrolment: 80 · Results not recorded

NCT03907501 ↗NAterminated

Effects of organic Triphala and VSL#3 probiotic supplementation on stool microbiome profiles and inflammation in healthy elderly subjects

Human Microbiome

Enrolment: 75 · Results not recorded

NCT00831337 ↗NAcompleted

Study of probiotics in liver cirrhosis patients with portal hypertension

Liver Cirrhosis · Portal Hypertension · Encephalopathy

Enrolment: 33 · Results not recorded

NCT00786123 ↗NAcompleted

Exploring the mechanism of probiotic combination VSL#3 in irritable bowel syndrome

Irritable Bowel Syndrome

Enrolment: 40 · Results not recorded

NCT03423589 ↗NAcompleted

Modulation of type 1 diabetes susceptibility through VSL#3 probiotic-induced alterations in the intestinal microbiota

Type 1 Diabetes Mellitus

Enrolment: 30 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24138544 ↗2013Reported benefit

The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury

RatChemical/toxinMalen = 56 rats total, 8 per group across 7 groupsIntragastric via stomach tubeVSL#3 0.6 g/kg; glutamine 0.3 g/kg; heat-killed VSL#3 0.6 g…30 minutes before each alcohol administration, prophylactic

Model: Acute alcoholic intestinal and liver injury induced by three intragastric doses of 40 percent alcohol at 5 g/kg body weight given every 12 hours after a 12 hour fast

Alcohol raised plasma TNF-alpha (383.08 +/- 20.21 versus control 174.69 +/- 20.68) and endotoxin (1.57 +/- 0.11 versus 0.19 +/- 0.10) and reduced occludin and ZO-1 mRNA and protein. VSL#3 (TNF-alpha 201.54 +/- 26.56, endotoxin 0.34 +/- 0.10), heat-killed VSL#3 and glutamine each significantly rever…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…